1Division of Infectious Diseases,Washington University School of Medicine,St Louis, Missouri.
2Division of Pulmonary and Critical Care Medicine,Washington University School of Medicine,St Louis,Missouri.
Infect Control Hosp Epidemiol. 2018 Jan;39(1):12-19. doi: 10.1017/ice.2017.254. Epub 2017 Dec 17.
OBJECTIVE To determine incidence of and risk factors for readmissions with multidrug-resistant organism (MDRO) infections among patients with previous MDRO infection. DESIGN Retrospective cohort of patients admitted between January 1, 2006, and October 1, 2015. SETTING Barnes-Jewish Hospital, a 1,250-bed academic tertiary referral center in St Louis, Missouri. METHODS We identified patients with MDROs obtained from the bloodstream, bronchoalveolar lavage (BAL)/bronchial wash, or other sterile sites. Centers for Disease Control and prevention (CDC) and European CDC definitions of MDROs were utilized. All readmissions ≤1 year from discharge from the index MDRO hospitalization were evaluated for bloodstream, BAL/bronchial wash, or other sterile site cultures positive for the same or different MDROs. RESULTS In total, 4,429 unique patients had a positive culture for an MDRO; 3,453 of these (78.0%) survived the index hospitalization. Moreover, 2,127 patients (61.6%) were readmitted ≥1 time within a year, for a total of 5,849 readmissions. Furthermore, 512 patients (24.1%) had the same or a different MDRO isolated from blood, BAL/bronchial wash, or another sterile site during a readmission. Bone marrow transplant, end-stage renal disease, lymphoma, methicillin-resistant Staphylococcus aureus, or carbapenem-resistant Pseudomonas aeruginosa during index hospitalization were factors associated with increased risk of having an MDRO isolated during a readmission. MDROs isolated during readmissions were in the same class of MDRO as the index hospitalization 9%-78% of the time, with variation by index pathogen. CONCLUSIONS Readmissions among patients with MDRO infections are frequent. Various patient and organism factors predispose to readmission. When readmitted patients had an MDRO, it was often a pathogen in the same class as that isolated during the index admission, with the exception of Acinetobacter (~9%). Infect Control Hosp Epidemiol 2018;39:12-19.
确定有先前耐多药生物体(MDRO)感染史的患者再次入院时MDRO 感染的发生率和危险因素。
2006 年 1 月 1 日至 2015 年 10 月 1 日期间住院患者的回顾性队列。
密苏里州圣路易斯市 1250 张病床的学术三级转诊中心巴恩斯-犹太医院。
我们确定了从血液、支气管肺泡灌洗(BAL)/支气管冲洗或其他无菌部位获得 MDRO 的患者。采用疾病控制和预防中心(CDC)和欧洲 CDC 的 MDRO 定义。对从指数 MDRO 住院出院后 1 年内所有再入院的患者进行评估,以确定血液、BAL/支气管冲洗或其他无菌部位培养出相同或不同 MDRO。
共有 4429 名患者的 MDRO 培养呈阳性;其中 3453 名(78.0%)在指数住院期间存活。此外,2127 名患者(61.6%)在一年内至少再入院一次,总计 5849 次再入院。此外,512 名患者(24.1%)在再入院期间从血液、BAL/支气管冲洗或另一个无菌部位分离出相同或不同的 MDRO。指数住院期间的骨髓移植、终末期肾病、淋巴瘤、耐甲氧西林金黄色葡萄球菌或耐碳青霉烯类铜绿假单胞菌是再入院时分离出 MDRO 的风险增加的因素。再入院期间分离出的 MDRO 在 9%-78%的时间与指数住院期间的 MDRO 属于同一类别,具体取决于指数病原体。
MDRO 感染患者的再入院率很高。各种患者和病原体因素易导致再入院。当再入院患者有 MDRO 时,它通常是与指数入院期间分离出的病原体属于同一类别的病原体,除不动杆菌(~9%)外。
感染控制与医院流行病学 2018;39:12-19。